Jeff Livingstone, PhD
Jeff Livingstone, PhD, is the CEO of Igia Pharmaceuticals, a pediatric rare disease company developing a novel therapy to address hypertrophic cardiomyopathy in infants and children with Noonan syndrome or Noonan syndrome with multiple lentigines. He is also CEO of Igia's parent company LBR, a specialty clinical and regulatory development organization.
For nearly three decades Dr. Livingstone has been involved in drug research and development on both the technical and commercial sides. He has 20 years of corporate development and new venture strategy experience across a wide variety of business types, from small privately owned companies to global divisions of large public corporations. As a former member of the MIT Venture Mentoring Service and regular participant in the MIT Enterprise Forum, Dr. Livingstone also helped to establish several new companies, including Xpogen and CyberMedica.
Dr. Livingstone received his PhD in physical biochemistry from the University of Wisconsin at Madison and his BS in biochemistry from the University of Missouri at Columbia.
Executive Chairman, Board of Directors
James (Jim) Mullen joined the Editas medicine board of directors as chairman in March 2018 and in February 2021 was appointed as President and CEO. In June 2022, Jim became Executive Chairman.
Jim is a recognized biotech leader with more than 40 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. Previously, he served as chief executive officer of Patheon NV, a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. (Thermo Fisher), in August 2017. Before joining Patheon, Jim served as chief executive officer and president at Biogen, Inc. (Biogen), one of the world's largest biotechnology companies. Prior to being named chief executive officer, he held various operating positions at Biogen, including chief operating officer, vice president, international, and vice president, operations.
Jim also serves on the board of directors of Thermo Fisher Scientific. He previously served on the board of directors of Patheon, Biogen, and PerkinElmer, Inc. He was also chairman of the board of directors of the Biotechnology Innovation Organization.
Jim holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.
Prakash Raman, PhD
President, Chief Executive Officer
Prakash Raman has served as Ribon’s president, chief executive officer and board member since February 2022. Dr. Raman brings to Ribon decades of biopharmaceutical business development and executive leadership experience, blending his scientific background, program and portfolio management and strong business development experience. Prior to joining Ribon, he served as Senior Partner, Chief Business Development Officer at Flagship Pioneering from October 2019 to February 2022, where he leveraged the platforms and assets in Flagship’s network to generate opportunities for significant value creation. Prior to Flagship, Dr. Raman spent nearly fourteen years at Novartis, most recently as Vice President, Global Head of Novartis Institutes for Biomedical Research (NIBR) Business Development and Licensing (BD&L). During his time at Novartis, Dr. Raman was instrumental in forging key collaborations in immuno-oncology, executing many out-licensing opportunities and guiding the acquisitions of Advanced Accelerator Applications, Endocyte, IFM Tre and Selexys. In addition, he has led cross-functional drug discovery and early development project teams that successfully progressed compounds to clinical testing in patients. Prior to Novartis, Dr. Raman spent six years as a Senior Scientist at Millennium Pharmaceuticals and two years as a post-doctoral fellow at The Scripps Research Institute. He completed his undergraduate work at the Indian Institute of Technology, Bombay, and received his Ph.D. in Organic and Medicinal Chemistry from the University of Wisconsin-Madison.
Chief Executive Officer
Alex Waldron is chief executive officer at Wellinks, a healthcare company on a mission to help patients with COPD live fully and breathe freely. Offering the first-ever integrated, virtual COPD management system, Wellinks supports patients through virtual pulmonary rehabilitation, health coaching, and monitoring through connected devices and an easy-to-use smartphone app.
Alex is a global healthcare business executive with 25+ years of experience leading large pharmaceutical, fully integrated biopharmaceutical, digital healthcare, and startup organizations. In previous roles, Alex was one of the original members of the Pear Therapeutics management team, architected the structure and growth of several divisions at Biogen, and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.